（文章来源：证券日报） 证券日报网讯 12月19日晚间，特一药业发布公告称，截至目前，公司已累计归还500万元资金至可转债 募集资金专用账户，剩余暂时补充流动资金的2，000万元闲置募集资金将在到期之前归还。 ...

本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假记载、 误导性陈述或重大遗漏。 特一药业集团股份有限公司（以下简称"特一药业"或"公司"）于 2025 年 5 月 21 日召开第五届董事会第三十二次会议，审议通过了《关于使用可转债部分闲置募集资 金暂时补充流动资金的议案》，为了有效提高募集资金的使用效率，减少财务费用，降 低运营成本，维护公司和股东利益，在确保公司可转换公司债券募集资金投资项目按进 度实施的前提下，同意公司使用不超过人民币 2,500 万元可转债闲置募集资金暂时补充 流动资金，董事会审议通过后，自首次办理暂时补充流动资金之日起，不超过 12 个月， 到期前归还至募集资金专用账户。具体内容详见公司于 2025 年 5 月 22 日刊登于法定媒 体及巨潮资讯网（http://www.cninfo.com.cn/）上的《关于使用可转债部分闲置募集 资金暂时补充流动资金的公告》（公告编号：2025-033）。 在使用可转债部分闲置募集资金暂时补充流动资金期间，公司通过合理安排，资金 运作良好。2025 年 12 月 18 日，公司将上述用于暂时补充流动资金的募集资金人民币 500 万 ...

New Stock Listings - Jingchuang Electric (920035) listed at an issuance price of 12.10 on December 2, 2025[1] - Tianpu Co., Ltd. (605255) is in the offer period from November 20 to December 19, 2025[1] Market Alerts - ST Suwu (600200) enters the delisting arrangement period starting December 9, 2025[1] - Jianglong Shipbuilding (300589) reported severe abnormal fluctuations[1] Recent Announcements - Multiple companies including Beida Pharmaceutical (000788) and ST Green Health (002868) have recent announcements regarding their stock activities[1] - A total of 30 companies have been flagged for abnormal trading activities in the last week[2]

Group 1 - The flu-related concept has become active again, with Haiwang Bio hitting the daily limit up [2] - Yue Wannianqing has increased by over 12% [2] - Other companies such as Guangji Pharmaceutical, Hendi Pharmaceutical, Te Yi Pharmaceutical, Jinshi Yiyao, and Xinhua Pharmaceutical have also seen gains [2]

Investment Rating - The industry rating is maintained at "Overweight" [8] Core Views - The market performance of the traditional Chinese medicine (TCM) sector showed a slight increase of 1.29%, which is the smallest among secondary sub-sectors [1] - The price governance of Chinese patent medicines is being actively implemented across multiple regions, aiming to create a unified and competitive drug market [4][5] - The valuation metrics for the TCM sector indicate a PE (ttm) of 27.72X and a PB (lf) of 2.33X, with both metrics showing slight increases compared to the previous week [2] Market Performance - The TCM sector reported a market index of 6501.99 points, reflecting a 1.29% increase over the last week [1] - The overall pharmaceutical and biological sector index rose to 8430.03 points, with a 2.67% increase [1] Valuation Metrics - The TCM sector's PE (ttm) is at 27.72X, up by 0.36X week-on-week, with a one-year maximum of 30.26X and a minimum of 24.72X [2] - The PB (lf) stands at 2.33X, increasing by 0.02X from the previous week, with a one-year maximum of 2.54X and a minimum of 2.17X [2] Supply Chain Insights - The market for TCM raw materials has shown signs of recovery, with a price index of 225.55 points, reflecting a 0.4% increase from the previous week [3] - The market sentiment for TCM raw materials is improving, with increased foot traffic and positive investment sentiment [3] Policy and Regulatory Environment - Multiple regions have initiated price governance for Chinese patent medicines, focusing on high-priced products with significant price discrepancies [4][5] - The ongoing supply-side reforms are expected to reshape competitive factors within the industry, with a shift from channel-driven to value and cost-driven competition [5] Investment Recommendations - The report suggests focusing on three main investment themes: price governance, consumption recovery, and state-owned enterprise reform [11] - Specific recommendations include companies with strong R&D capabilities, unique products, and those less affected by centralized procurement [12]

Market Overview - On November 28, A-shares saw a collective rise in the three major indices, with the Shanghai Composite Index up 0.34% to 3888 points, the Shenzhen Component Index up 0.85%, and the ChiNext Index up 0.7% [1] - Over 4100 stocks in the market experienced gains, with market hotspots focusing on titanium dioxide, Hainan, satellite internet, and commercial aerospace sectors, while traditional Chinese medicine stocks declined and flu-related stocks corrected [1] Key Stocks - Guosheng Technology (603778) rose by 9.96%, marking its 10th consecutive trading day of gains, driven by solid-state batteries and photovoltaic technology [2] - Dream Home (603216) increased by 10.02%, with its stock price rising due to the termination of acquisition plans and chip concepts [2] - Jinfu Technology (003018) saw a 10.03% rise, planning to acquire Lanyuan Technology [2] - Aerospace Development (002413) surged by 10.06%, benefiting from commercial aerospace and radar technology [2] - The top net buying stocks on the day included Aerospace Development, Dongtian Micro (301183), and LeiKe Defense (002413), with net purchases of 3.92 billion, 2.13 billion, and 2.05 billion respectively [2][4] Sector Performance - The commercial aerospace sector showed strong performance, with Aerospace Development achieving a 10.02% increase and a trading volume of 51.71 billion [4][10] - The military industry sector faced declines, with stocks like Jianglong Shipbuilding dropping over 10% and Aerospace Development hitting the daily limit [10] - The semiconductor and technology sectors also saw significant movements, with stocks like Dongtian Micro and Qian Zhao Optoelectronics experiencing gains of 20% and 20.01% respectively [10][15] Trading Dynamics - The top net selling stocks included Zhongsheng Pharmaceutical, Te Yi Pharmaceutical, and Xinhua Du, with net sales of 2.77 billion, 1.90 billion, and 1.53 billion respectively [5][6] - The trading volume and turnover rates for several stocks were notably high, with some stocks like Dongtian Micro and Qian Zhao Optoelectronics achieving turnover rates of 29.00% and 15.60% respectively [6][15] - The market showed a mix of strong buying interest in certain sectors while facing selling pressure in others, indicating a diverse trading environment [6][10]

Group 1 - The hepatitis concept sector declined by 0.31%, ranking among the top declines in concept sectors, with companies like Zhongsheng Pharmaceutical and Guangji Pharmaceutical hitting the limit down [1][2] - Major stocks in the hepatitis sector that saw significant outflows include Zhongsheng Pharmaceutical with a net outflow of 684 million yuan, followed by Te Yi Pharmaceutical and Pian Zai Huang with net outflows of 112 million yuan and 81 million yuan respectively [2][3] - Conversely, stocks that experienced net inflows include Baihua Pharmaceutical, Huadong Medicine, and Kangzhi Pharmaceutical, with inflows of 97.75 million yuan, 43.11 million yuan, and 21.20 million yuan respectively [6] Group 2 - The top gainers in the hepatitis sector included Baihua Pharmaceutical, which rose by 10.01%, followed by Chengda Pharmaceutical and Kangzhi Pharmaceutical with increases of 4.79% and 3.00% respectively [1][6] - The overall market sentiment for the hepatitis sector appears negative, as evidenced by the significant net outflows and the number of stocks declining in value [2][3] - The trading volume for Zhongsheng Pharmaceutical was notably high, with a turnover rate of 18.78%, indicating active trading despite the price drop [2][3]

Group 1 - The Chinese medicine sector experienced a decline of 0.83% on November 28, with Yue Wannianqing leading the drop [1] - The Shanghai Composite Index closed at 3888.6, up 0.34%, while the Shenzhen Component Index closed at 12984.08, up 0.85% [1] - Key stocks in the Chinese medicine sector showed mixed performance, with Tai Long Pharmaceutical rising by 5.37% to a closing price of 8.04 [1] Group 2 - Yue Wannianqing saw a significant drop of 13.71%, closing at 22.84, with a trading volume of 296,100 shares [2] - Other notable declines included Zhongsheng Pharmaceutical, which fell by 10.00% to 23.95, and Te Yi Pharmaceutical, which decreased by 6.41% to 14.01 [2] - The overall net capital flow in the Chinese medicine sector indicated a net outflow of 981 million yuan from main funds, while retail investors contributed a net inflow of 766 million yuan [2]

Core Viewpoint - The stock of Te Yi Pharmaceutical Group Co., Ltd. has experienced an abnormal trading fluctuation, with a cumulative closing price increase exceeding 20% over three consecutive trading days from November 25 to November 27, 2025 [1][2]. Summary by Sections Stock Trading Abnormal Fluctuation - Te Yi Pharmaceutical's stock price has deviated significantly, indicating abnormal trading activity as per Shenzhen Stock Exchange regulations [1]. Company Verification and Situation - The company confirms that its operations are normal and there have been no significant changes in its internal or external business environment [1]. - There are no corrections or supplements needed for previously disclosed information [1]. - No major undisclosed information has been reported in public media that could impact the stock price [1]. - The company, its controlling shareholders, and actual controllers have no undisclosed significant matters related to the company [1][2]. Disclosure of Information - The board of directors confirms that there are no undisclosed matters that should be reported according to the Shenzhen Stock Exchange's listing rules [2]. - The board has not been made aware of any significant undisclosed information that could affect the company's stock and its derivatives [2].

证券代码：002728 证券简称：特一药业 公告编号：2025-063 特一药业集团股份有限公司 股票交易异常波动公告 3、公司未发现近期公共传媒报道了可能或已经对公司股票交易价格产生较大影响 的未公开重大信息。 4、公司、控股股东和实际控制人不存在关于本公司的应披露而未披露的重大事项， 不存在处于筹划阶段的重大事项。 5、公司控股股东、实际控制人在股票异常波动期间不存在买卖公司股票的情形。 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假记载、 误导性陈述或重大遗漏。 一、股票交易异常波动的情况介绍 特一药业集团股份有限公司（以下简称"公司"；证券简称：特一药业；证券代码： 002728）股票连续三个交易日内（2025 年 11 月 25 日、2025 年 11 月 26 日、2025 年 11 月 27 日）收盘价格涨幅偏离值累计超过 20%。根据深圳证券交易所的相关规定，属于股 票交易异常波动的情况。 二、公司关注并核实的相关情况 针对公司股票交易异常波动，公司董事会对公司、控股股东及实际控制人就相关事 项进行了核实，现就有关情况说明如下： 1、公司经营正常，近期公司经营情况、内外部经 ...